SEARCH

SEARCH BY CITATION

References

  • 1
    Moester MJ, Papapoulos SE, Löwik CW, van Bezooijen RL. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int. 2010; 87:99107.
  • 2
    Monroe DG, McGee-Lawrence ME, Oursler MJ, Westendorf JJ. Update on Wnt signaling in bone cell biology and bone disease. Gene. 2012; 492:118.
  • 3
    Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res. 2011; 26:281222.
  • 4
    Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL. Melton LJ 3rd, Khosla S. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011; 26:3739.
  • 5
    Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int. 2013; 24:48994.
  • 6
    Arasu A, Cawthon PM, Lui LY, Do TP, Arora PS, Cauley JA, Ensrud KE, Cummings SR. Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab. 2012; 97:202732.
  • 7
    Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, Hampson G. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int. 2012; 90:47380.
  • 8
    Sheng Z, Tong D, Ou Y, Zhang H, Zhang Z, Li S, Zhou J, Zhang J, Liao E. Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women. Clin Endocrinol (Oxf). 2012; 76:797801.
  • 9
    Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschitz A, Pieber TR, Fahrleitner-Pammer A. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab. 2012; 97:14854.
  • 10
    Morse LR, Sudhakar S, Danilack V, Tun C, Lazzari A, Gagnon DR, Garshick E, Battaglino RA. Association between sclerostin and bone density in chronic spinal cord injury. J Bone Miner Res. 2012; 27:3529.
  • 11
    Cejka D, Jäger-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG, Diarra D, Patsch JM, Kainberger F, Bohle B, Haas M. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant. 2012; 27:22630.
  • 12
    Mödder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res. 2011; 26:2734.
  • 13
    Yu EW, Kumbhani R, Siwila-Sackman E, Leder BZ. Acute decline in serum sclerostin in response to PTH infusion in healthy men. J Clin Endocrinol Metab. 2011; 96:E184851.
  • 14
    Gatti D, Viapiana O, Idolazzi L, Fracassi E, Rossini M, Adami S. The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab. 2011; 96:15559.
  • 15
    Chaitou A, Boutroy S, Vilayphiou N, Munoz F, Delmas PD, Chapurlat R, Szulc P. Association between bone turnover rate and bone microarchitecture in men: the STRAMBO study. J Bone Miner Res. 2010; 25:231323.
  • 16
    Chaitou A, Boutroy S, Vilayphiou N, Varennes A, Richard M, Blaizot S, Munoz F, Delmas PD, Goudable J, Chapurlat R, Szulc P. Association of bone microarchitecture with parathyroid hormone concentration and calcium intake in men: the STRAMBO study. Eur J Endocrinol. 2011; 165:1519.
  • 17
    Szulc P, Munoz F, Marchand F, Chapuy MC, Delmas PD. Role of vitamin D and parathyroid hormone in the regulation of bone turnover and bone mass in men: the MINOS study. Calcif Tissue Int. 2003; 73:52030.
  • 18
    Szulc P, Hawa G, Boutroy S, Vilayphiou N, Schoppet M, Chapurlat R, Hofbauer LC. Cortical bone status is associated with serum osteoprotegerin concentration in men: the STRAMBO study. J Clin Endocrinol Metab. 2011; 96:221626.
  • 19
    Szulc P, Uusi-Rasi K, Claustrat B, Marchand F, Beck TJ, Delmas PD. Role of sex steroids in the regulation of bone morphology in men. The MINOS study. Osteoporos Int. 2004; 15:90917.
  • 20
    Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999; 84:366672.
  • 21
    Szulc P, Claustrat B, Munoz F, Marchand F, Delmas PD. Assessment of the role of 17beta-oestradiol in bone metabolism in men: does the assay technique matter?. The MINOS study. Clin Endocrinol. 2004; 61:44757.
  • 22
    Rolland T, Boutroy S, Vilayphiou N, Blaizot S, Chapurlat R, Szulc P. Poor trabecular microarchitecture at the distal radius in older men with increased concentration of high-sensitivity C-reactive protein—the STRAMBO study. Calcif Tissue Int. 2012; 90:496506.
  • 23
    Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007; 53:76672.
  • 24
    Boutroy S, Bouxsein ML, Munoz F, Delmas PD. In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2005; 90:650815.
  • 25
    Szulc P, Blaizot S, Boutroy S, Vilayphiou N, Boonen S. Chapurlat R Impaired bone microarchitecture at the distal radius in older men with low muscle mass and grip strength—the STRAMBO study. J Bone Miner Res. 2013; 28:16978.
  • 26
    Szulc P, Boutroy S, Vilayphiou N, Chaitou A, Delmas PD, Chapurlat R. Cross-sectional analysis of the association between fragility fractures and bone microarchitecture in older men: the STRAMBO study. J Bone Miner Res. 2011; 26:135867.
  • 27
    Blaizot S, Boutroy S, Vilayphiou N, Boonen S, Chapurlat R, Szulc P. Poor bone microarchitecture in older men with impaired physical performance—the STRAMBO study. Osteoporos Int. 2012; 23:278596.
  • 28
    Fardellone P, Sebert JL, Bouraya M, Bonidan O, Leclercq G, Doutrellot C, Bellony R, Dubreuil A. Evaluation de la teneur en calcium du regime alimentaire par autoquestionnaire frequentiel [Evaluation of the calcium content of diet by frequential self-questionnaire]. Rev Rhum Mal Osteoartic. 1991; 58:99103. French.
  • 29
    Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CW, Reeve J. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005; 19:18424.
  • 30
    Power J, Poole KE, van Bezooijen R, Doube M, Caballero-Alías AM, Lowik C, Papapoulos S, Reeve J, Loveridge N. Sclerostin and the regulation of bone formation: effects in hip osteoarthritis and femoral neck fracture. J Bone Miner Res. 2010; 25:186776.
  • 31
    Szulc P, Garnero P, Munoz F, Marchand F, Delmas PD. Cross-sectional evaluation of bone metabolism in men. J Bone Miner Res. 2001; 16:164250.
  • 32
    Szulc P, Bertholon C, Borel O, Marchand F, Chapurlat R. Lower fracture risk in older men with higher sclerostin concentration—a prospective analysis from the MINOS study. J Bone Miner Res. Epub 2012 Nov 19. DOI: 10.1002/jbmr.1823
  • 33
    Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011; 6:e25900.
  • 34
    Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011; 26:1926.
  • 35
    Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2008; 283:586675.
  • 36
    Moustafa A, Sugiyama T, Prasad J, Zaman G, Gross TS, Lanyon LE, Price JS. Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered. Osteoporos Int. 2012; 23:122534.
  • 37
    Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab. 2010; 95:224853.
  • 38
    Spatz JM, Fields EE, Yu EW, Pajevic PD, Bouxsein ML, Sibonga JD, Zwart SR, Smith SM. Serum sclerostin increases in healthy adult men during bed rest. J Clin Endocrinol Metab. 2012; 97:E173640.
  • 39
    Urano T, Shiraki M, Ouchi Y, Inoue S. Association of circulating sclerostin levels with fat mass and metabolic disease–related markers in Japanese postmenopausal women. J Clin Endocrinol Metab. 2012; 97:E14737.
  • 40
    Zaidi M, Buettner C, Sun L, Iqbal J. Minireview: the link between fat and bone: does mass beget mass?. Endocrinology. 2012; 153:20705.
  • 41
    Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-Senani NS, Qari MH, Mousa SA. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis research study. J Bone Miner Res. 2012; 27:2592602.
  • 42
    Callewaert F, Bakker A, Schrooten J, Van Meerbeek B, Verhoeven G, Boonen S, Vanderschueren D. Androgen receptor disruption increases the osteogenic response to mechanical loading in male mice. J Bone Miner Res. 2010; 25:12431.